Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed multiple myeloma (MM). BMMC were treated ex vivo wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Foureau, David M., Bhutani, Manisha, Robinson, Myra, Guo, Fei, Pham, Duy, Buelow, Ben, Steuerwald, Nury, Rigby, Katherine, Tjaden, Elise, Leonidas, Marina, Paul, Barry A., Atrash, Shebli, Ndiaye, Ami, Symanowski, James T., Voorhees, Peter M., Usmani, Saad Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175895/
https://www.ncbi.nlm.nih.gov/pubmed/35847733
http://dx.doi.org/10.1002/jha2.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175895/
https://www.ncbi.nlm.nih.gov/pubmed/35847733
http://dx.doi.org/10.1002/jha2.69

Ejemplares similares